What Analysts Project for Thermo Fisher

Wall Street analysts’ estimates

Wall Street analysts estimate Thermo Fisher Scientific (TMO) to report 14.1% growth in revenues to ~$23.9 billion in full-year 2018 as compared to $20.9 billion during 2017. EPS is estimated to be $10.99 during 2018 as compared to EPS of $9.49 during 2017. Analysts estimate the net adjusted income to increase to $4.5 billion during 2018 as compared to the net adjusted income of $3.8 billion during 2017.

What Analysts Project for Thermo Fisher

The above chart compares changes in analysts’ recommendations for Thermo Fisher Scientific since January 2018.

Analysts’ ratings

Thermo Fisher Scientific’s stock price has increased by nearly 22.1% in the last 12 months and nearly 24.5% in 2018 year-to-date. Analysts estimate the stock might increase by ~7.0% over the next 12 months. Wall Street analysts have a 12-month target price of $252.86 per share as compared to the last price of $236.43 per share as of September 11, 2018.

As of September 12, 2018, 16 analysts are tracking Thermo Fisher Scientific. Of these, eight analysts recommend a “strong buy,” seven analysts recommend a “buy,” and one analyst recommends a “hold.” The consensus rating for Thermo Fisher Scientific stands at 1.56, which represents a “strong buy” for momentum investors as well as long-term growth investors. Changes in analysts’ estimates and recommendations are based on the changing trends in stock prices and the performance of the company.

The iShares Global Healthcare ETF (IXJ) holds 1.9% of its total investments in Thermo Fisher (TMO), 7.2% in Johnson & Johnson (JNJ), 3.7% in Merck & Co. (MRK), and 2.5% in Medtronic (MDT).